 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 PR Newswire SAN...

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics...

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead...

Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It...

Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.

One of the hottest areas of the pharmaceutical industry right now is the weight loss treatment space. Novo Nordisk and Eli Lilly have been the primary innovators. Their groundbreaking glucagon-like...

Is it Too Late to Buy Viking Therapeutics Stock?

Viking Therapeutics (NASDAQ: VKTX) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a...

1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now

Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher...

Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill

Viking Therapeutics: Future Weight Loss Heavyweight...

Viking Therapeutics: Future Weight Loss Heavyweight?

For Immediate ReleaseChicago, IL &ndash; April 1, 2024 &ndash; Today, Zacks Investment Ideas feature highlights SPDR S&P Biotech ETF XBI, iShares Biotech ETF IBB, Viking Therapeutics VKTX and...

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

In this article, we will be taking a look at the 20 most obese countries in Asia. If you do not want to learn about the global obesity crisis, head straight to the 5 Most Obese Countries in Asia.
The...

20 Most Obese Countries in Asia

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Volume (M)	1,029.00
52-Wk High	$99.41
52-Wk Low	$8.28

VKTX Viking Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals